Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
Rights to certain drugs
|
| gptkbp:collaborates_with |
Healthcare Providers
|
| gptkbp:employs |
Pharmaceutical Scientists
|
| gptkbp:engages_in |
Public Health Initiatives
|
| gptkbp:focuses_on |
gptkb:Research_Institute
|
| gptkbp:founded |
gptkb:2008
|
| gptkbp:has_part |
gptkb:legal_case
|
| gptkbp:has_product |
gptkb:Ribavirin
gptkb:Oseltamivir gptkb:Lacosamide gptkb:Ciprofloxacin Sofosbuvir |
| gptkbp:has_website |
www.shionogi.com
|
| gptkbp:headquarters |
gptkb:Florham_Park,_New_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shionogi Pharma, LLC
|
| gptkbp:is_active_in |
Clinical Research
|
| gptkbp:is_known_for |
Innovative Therapies
|
| gptkbp:offers |
Antiviral Medications
|
| gptkbp:operates_in |
gptkb:United_States
|
| gptkbp:parent_company |
gptkb:Shionogi_&_Co.,_Ltd.
|
| gptkbp:participates_in |
Global Health Partnerships
|
| gptkbp:specializes_in |
Infectious Diseases
|
| gptkbp:supports |
Patient Assistance Programs
|
| gptkbp:bfsParent |
gptkb:Shionogi
|
| gptkbp:bfsLayer |
6
|